Sanofi reports strong Q3 financial results
Net sales grew 14.3%. The company expanded its Regeneron alliance and focused on Immunology, Rare Diseases, and Vaccines.
See the latest news and media coverage for Sanofi. We track all announcements, press releases, and industry mentions in real time, all in one place.
R&D-driven, AI-powered biopharmaceutical company
sanofi.comLast updated
In short: Sanofi expanded its Regeneron alliance in a deal valued at up to $8 billion.
Net sales grew 14.3%. The company expanded its Regeneron alliance and focused on Immunology, Rare Diseases, and Vaccines.
Full press release with detailed insights is available via provided link.
Long-term phase 2b results show maintained efficacy and safety at week 44. The antibody targets TL1A inflammation in IBD patients.
Sanofi pays $1 billion upfront to jointly develop and commercialize next-generation immunology treatments with up to $7 billion in potential milestones.
The French drugmaker focuses on pricier late-stage deals rather than restructuring ahead of Dupixent's 2031 expiry.
Sanofi raised its forecasts for sales and profit this year for a second straight quarter on rising demand for its top-selling skin and asthma drug...
Investors look past French turmoil to find bargains in multinationals like TotalEnergies, LVMH, Michelin, and Sanofi.
Teva Pharmaceutical Industries Ltd. ( TEVA) and Sanofi ( SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis...
Track Sanofi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sanofi and other trending companies.